One such internal regulator, the cytokine-inducible SH2-containing protein (CISH), has been knocked out using the CRISPR-Cas9 system and has been demonstrated to enhance reactivity towards cancer antigens in TIL therapy [58]. Here, CISH is linked to cancer.